Interleukin-1 Receptor Antagonist Anakinra For Patients With Severe Covid-19:a Meta-analysis

Objectives: Using Meta analysis to evaluate the efficacy,related adverse reactions,and complications of Anakinra in the treatment of severe COVID-19,so as to provide evidence for Anakinra in the treatment of severe COVID-19.Methods: Using computer to search the English databases Pub Med(2019.12.01 to 2021.11.11),Embase(2019.12.01 to 2021.11.11),and The Cochrane Library(2019.12.01 to 2021.11.11).Collecting all studies related to patients with severe COVID-19 pneumonia who received Anakinra and conventional treatment and only received conventional treatment.The main endpoint is the mortality rate with the longest follow-up period.Adverse reactions such as concurrent bacteremia and elevated transaminases were also analyzed.According to the inclusion and removal criteria,document screening,data fetch and methodological quality evaluation of the obtained literature were carried out.Analyses were performed with Review Manager version5.4.1.Results: Six observational studies involving 463(Anakinra group240,Conventional group223)patients were included.Overall mortality of patients treated with anakinra was significantly lower than mortality in the control group [RR 0.42 CI95%(0.31,0.58)P<0.0001].There was no significantly different in complications such as bacteremia [RR 1.26 CI95%(0.80,1.99)P=0.32] and transaminase increased [RR 0.77 CI95 %(0.28,2.14)P=0.62] with the control group.Conclusions: Through the meta-analysis of the efficacy of Anakinra in the treatment of severe COVID-19,the use of Anakinra in the treatment of severe COVID-19 is safe,it can reduce the mortality rate of patients,and dose not increase the occurrence of complications such as elevated transaminase and bacteremia.